Standout Papers

Tumor immunotherapies by immune checkpoint inhibitors (ICIs); the pros and cons 2022 2026 2023 2024270
  1. Tumor immunotherapies by immune checkpoint inhibitors (ICIs); the pros and cons (2022)
    Adel Naimi, Rebar N. Mohammed et al. Cell Communication and Signaling

Immediate Impact

51 standout
Sub-graph 1 of 20

Citing Papers

MDM2 Inhibitors for Cancer Therapy: The Past, Present, and Future
2024 Standout
Comprehensive review of CRISPR-based gene editing: mechanisms, challenges, and applications in cancer therapy
2024 Standout
2 intermediate papers

Works of Ehsan Razeghian being referenced

A deep insight into CRISPR/Cas9 application in CAR-T cell-based tumor immunotherapies
2021

Author Peers

Author Last Decade Papers Cites
Ehsan Razeghian 151 261 14 149 9 415
Ekaterina Zmievskaya 157 275 14 169 16 421
Chad A. Komar 146 255 7 196 5 444
Elisa Ruffo 125 237 10 193 10 404
Cassandra E. Burnett 119 214 19 202 9 417
Hans Anton Schloesser 132 242 11 165 10 424
Philippe De La Rochère 148 198 47 197 7 466
Irina Fernandez 175 192 98 239 9 466
Kerstin Schlüter 190 264 7 109 9 501
Gesa Schuebbe 143 235 12 160 5 432
Sanaz Taromi 150 286 7 136 13 396

All Works

Loading papers...

Rankless by CCL
2026